JP2023551935A5 - - Google Patents

Info

Publication number
JP2023551935A5
JP2023551935A5 JP2023533733A JP2023533733A JP2023551935A5 JP 2023551935 A5 JP2023551935 A5 JP 2023551935A5 JP 2023533733 A JP2023533733 A JP 2023533733A JP 2023533733 A JP2023533733 A JP 2023533733A JP 2023551935 A5 JP2023551935 A5 JP 2023551935A5
Authority
JP
Japan
Prior art keywords
binding protein
seq
protein according
binding
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023533733A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023551935A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/083465 external-priority patent/WO2022117526A1/en
Publication of JP2023551935A publication Critical patent/JP2023551935A/ja
Publication of JP2023551935A5 publication Critical patent/JP2023551935A5/ja
Pending legal-status Critical Current

Links

JP2023533733A 2020-12-02 2021-11-30 Il-7結合タンパク質および医学的療法におけるそれらの使用 Pending JP2023551935A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063120564P 2020-12-02 2020-12-02
US63/120,564 2020-12-02
PCT/EP2021/083465 WO2022117526A1 (en) 2020-12-02 2021-11-30 Il-7 binding proteins and their use in medical therapy

Publications (2)

Publication Number Publication Date
JP2023551935A JP2023551935A (ja) 2023-12-13
JP2023551935A5 true JP2023551935A5 (https=) 2024-12-04

Family

ID=78844686

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023533733A Pending JP2023551935A (ja) 2020-12-02 2021-11-30 Il-7結合タンパク質および医学的療法におけるそれらの使用

Country Status (15)

Country Link
US (3) US11802150B2 (https=)
EP (1) EP4255928A1 (https=)
JP (1) JP2023551935A (https=)
KR (1) KR20230098288A (https=)
CN (1) CN116547002A (https=)
AR (1) AR124286A1 (https=)
AU (1) AU2021391493C1 (https=)
CA (1) CA3199648A1 (https=)
CL (1) CL2023001556A1 (https=)
CO (1) CO2023007851A2 (https=)
IL (1) IL303134A (https=)
MX (1) MX2023006294A (https=)
PH (1) PH12023551170A1 (https=)
TW (1) TWI821804B (https=)
WO (1) WO2022117526A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023227641A1 (en) * 2022-05-27 2023-11-30 Glaxosmithkline Intellectual Property Development Limited Use of tnf-alpha binding proteins and il-7 binding proteins in medical treatment

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1229125A4 (en) 1999-10-19 2005-06-01 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING A POLYPEPTIDE
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
NZ571596A (en) 2001-08-03 2010-11-26 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
EP1553975B8 (en) 2002-09-27 2023-04-12 Xencor, Inc. Optimized fc variants and methods for their generation
CA2512729C (en) 2003-01-09 2014-09-16 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
US20050164301A1 (en) 2003-10-24 2005-07-28 Avidia Research Institute LDL receptor class A and EGF domain monomers and multimers
AU2005269759A1 (en) 2004-07-21 2006-02-09 Glycofi, Inc. Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
UY32038A (es) 2008-08-08 2010-03-26 Glaxo Wellcome Mfg Pte Ltd Inmunoblobulinas anti-cd127 y sus usos
US8961967B2 (en) * 2009-11-30 2015-02-24 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions

Similar Documents

Publication Publication Date Title
CA2914170C (en) Interleukin-13 binding proteins
JP2018527952A5 (https=)
JP2020517249A5 (https=)
CN106573053B (zh) 干扰素α和ω抗体拮抗剂
JP2019522961A5 (https=)
KR20110110349A (ko) Il-1 결합 단백질
TW201124427A (en) IL-1 binding proteins
JP2011528902A5 (https=)
KR20110040886A (ko) 프로스타글란딘 e2 결합 단백질 및 이의 용도
JP2025037926A (ja) 抗il-17a/f抗体を用いた治療方法
TW201307388A (zh) Il-1結合蛋白
RU2013110874A (ru) Антитела против il-18r1 и их применения
AU2019200589A1 (en) Interferon alpha and omega antibody antagonists
JP2023551935A5 (https=)
JP2018534915A5 (https=)
JP2023551983A5 (https=)
JP2023512320A5 (https=)
RU2022107387A (ru) Межвидовые антитела к латентному tgf-бeta 1 и способы их применения
RU2020140526A (ru) Антитело против человеческого tlr7
AU2013200711A1 (en) Interleukin -13 binding proteins